Helix BioMedix Inc. (OTCMKTS:HXBM – Get Free Report) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 60 shares, a growth of ∞ from the May 31st total of 0 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 6 shares, the short-interest ratio is presently 10.0 days.
Helix BioMedix Stock Performance
HXBM opened at $1.79 on Wednesday. The firm has a 50-day moving average of $1.66 and a 200 day moving average of $1.79. Helix BioMedix has a fifty-two week low of $1.00 and a fifty-two week high of $6.45.
About Helix BioMedix
Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.
Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.
Recommended Stories
- Five stocks we like better than Helix BioMedix
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Helix BioMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioMedix and related companies with MarketBeat.com's FREE daily email newsletter.
